Asked
Whether she has made an assessment of the potential merits of age-based eligibility criteria for the respiratory syncytial virus vaccine.
Reply
In June 2023, the Joint Committee on Vaccination and Immunisation (JCVI) suggested an initial respiratory syncytial virus (RSV) programme to potentially vaccinate a cohort aged from 75 to 79 years old, and then for those turning 75 years old in subsequent...